Staging of renal cell carcinoma: Past, present, and future

Clinical Genitourinary Cancer

Volumn 5, Issue 3, 2006, Pages 190-197

  Nguyen, Carvell T ^a   Campbell, Steven C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adrenal involvement; Prognostic factors; TNM stage; Venous tumor thrombus

Indexed keywords

ADRENAL DISEASE; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL RESEARCH; HUMAN; KIDNEY CARCINOMA; MEDICAL DECISION MAKING; PROGNOSIS; RENOGRAPHY; REVIEW; VEIN THROMBOSIS;

EID: 33846703388     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.036     Document Type: Review

References (94)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
2. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States [see comment]. JAMA 1999; 281:1628-1631.
3. Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol Clin North Am 1993; 20:247-262.
4. Ficarra V, Artibani W. Staging system of renal cell carcinoma: current issues. Eur Urol 2006; 49:223-225.
5. Flocks RH, Kadesky MC. Malignant neoplasms of the kidney: an analysis of 353 patients followed 5 years or more. J Urol 1958; 79:196-201.
6. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101:297-301.
7. Sagalowsky AI, Kadesky KT, Ewalt DM, et al. Factors influencing adrenal metastasis in renal cell carcinoma. J Urol 1994; 151:1181-1184.
8. Sandock DS, Seftel AD, Resnick MI. Adrenal metastases from renal cell carcinoma: role of ipsilateral adrenalectomy and definition of stage. Urology 1997; 49:28-31.
9. Paul R, Mordhorst J, Leyh H, et al. Incidence and outcome of patients with adrenal metastases of renal cell cancer. Urology 2001; 57:878-882.
10. Han KR, Bui MH, Pantuck AJ, et al. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 2003; 169:899-903.
11. von Knobloch R, Varga Z, Schrader AJ, et al. All patients with adrenal metastasis from RCC will eventually die in tumor progression: there is no cure or benefit from simultaneous adrenalectomy. J Urol 2004; 171:115.
12. Lam JS, Patard JJ, Leppert JT, et al. Prognostic significance of T3a renal cell carcinoma with adrenal gland involvement: an international multicenter experience. J Urol 2005; 173:269.
13. Siemer S, Lehmann J, Loch A, et al. Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 2005; 173:33-37.
14. Thompson RH, Leibovich BC, Cheville JC, et al. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? [see comment] J Urol 2005; 173:918-921.
15. Skinner DG, Colvin RB, Vermillion CD, et al. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971; 28:1165-1177.
16. Harmer M. TNM Classification of Malignant Tumors. 2nd ed. Geneva: International Union Against Cancer; 1974.
17. Bassil B, Dosoretz D, Prout GR Jr. Classification and staging of renal cell carcinoma. CA Cancer J Clin 1985; 35:152-163.
18. Beahrs OH, Henson DE, Hutter RVP, et al. American Joint Committee on Cancer Manual far Staging of Cancer. 4th ed. Philadelphia, PA: JB Lippincott; 1992.
19. Hermanek P, Schrott KM. Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J Urol 1990; 144:238-241.
20. Guinan P, Saffrin R, Stuhldreher D, et al. Renal cell carcinoma: comparison of the TNM and Robson stage groupings. J Surg Oncol 1995; 59:186-189.
21. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80:992-993.
22. Thompson RH, Leibovich BC, Cheville JC, et al. Is renal sinus rat invasion the same as perinephric rat invasion for pT3a renal cell carcinoma? J Urol 2005; 174:1218-1221.
23. Javidan J, Stricker HJ, Tamboli P, et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 1999; 162:1277-1281.
24. Gettman MT, Blute ML, Spotts B, et al. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 2001; 91:354-361.
25. Minervini R, Minervini A, Fontana N, et al. Evaluation of the 1997 tumour, nodes and metastases classification of renal cell carcinoma: experience in 172 patients. BJU International 2000; 86:199-202.
26. Butler BP, Novick AC, Miller DP, et al. Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology 1995; 45:34-40.
27. Belldegrun A, Tsui KH, deKernion JB, et al. Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol 1999; 17:2868-2875.
28. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999; 162:1930-1933.
29. Frank I, Blute ML, Leibovich BC, et al. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005; 173:1889-1892.
30. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
31. Targonski PV, Frank W, Stuhldreher D, et al. Value of tumor size in predicting survival from renal cell carcinoma among tumors, nodes and metastases stage 1 and stage 2 patients. J Urol 1994; 152:1389-1392.
32. Lerner SE, Hawkins CA, Blute ML, et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol 1996; 155:1868-1873.
33. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20:2376-2381.
34. Igarashi T, Tobe T, Nakatsu HO, et al. The impact of a 4 cm. cutoff point for stratification of T1N0M0 renal cell carcinoma after radical nephrectomy. J Urol 2001; 165:1103-1106.
35. Vasselli JR, Yang JC, Linehan WM, et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001; 166:68-72.
36. Pantuck AJ, Zisman A, Belldegrun A. Biology of renal cell carcinoma: changing concepts in classification and staging. Semin Urol Oncol 2001; 19:72-79.
37. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003; 97:2995-3002.
38. Kontak JA, Campbell SC. Prognostic factors in renal cell carcinoma. Urol Clinics North Am 2003; 30:467-480.
39. Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004; 22:3316-3322.
40. Phillips CK, Taneja SS. The role of lymphadenectomy in the surgical management of renal cell carcinoma. Urol Oncol 2004; 22:214-223.
41. Leibovich BC, Cheville JC, Lohse CM, et al. Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved? [see comment] J Urol 2005; 173:716-719.
42. Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001; 166:6-18.
43. Frank I, Blute ML, Leibovich BC, et al. pT2 classification for renal cell carcinoma. Can its accuracy be improved? J Urol 2005; 173:380-384.
44. Giuliani L, Giberti C, Martorana G, et al. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990; 143:468-473.
45. Zisman A, Pantuck AJ, Chao D, et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol 2001; 166:54-58.
46. Cheville JC, Blute ML, Zincke H, et al. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol 2001; 166:453-456.
47. Sagalowsky AI. The 1997 TNM classification of renal cell carcinoma revisited: the pendulum swings back. Curr Opin Urol 2002; 12:371-373.
48. Elmore JM, Kadesky KT, Koeneman KS, et al. Reassessment of the 1997 TNM classification system for renal cell carcinoma. Cancer 2003; 98:2329-2334.
49. Ficarra V, Prayer-Galetti T, Novara G, et al. Tumor-size breakpoint for prognostic stratification of localized renal cell carcinoma. Urology 2004; 63:235-239.
50. Patard JJ, Shvarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 2004; 171:2181-2185.
51. Leibovich BC, Blute ML, Cheville JC, et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004; 171:1066-1070.
52. Campbell SC, Novick AC. Elective partial nephrectomy: is this advisable? Eur Urol 2006; 49:952-954.
53. Golimbu M, Joshi P, Sperber A, et al. Renal cell carcinoma: survival and prognostic factors. Urology 1986; 27:291-301.
54. Sene AP, Hunt L, McMahon RF, et al. Renal carcinoma in patients undergoing nephrectomy: analysis of survival and prognostic factors. Br J Urol 1992; 70:125-134.
55. Patard JJ, Leray E, Rodriguez A, et al. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol 2003; 44:226-232.
56. Swanson DA. The integration of surgery and systemic therapy for metastatic renal cell carcinoma. In: Ball TP, ed. AUA Update Series. Houston, TX: American Urological Association, Inc; 2002; Lesson 32.
57. Sosa RE, Muecke EC, Vaughan ED Jr, et al. Renal cell carcinoma extending into the inferior vena cava: the prognostic significance of the level of vena caval involvement. J Urol 1984; 132:1097-1100.
58. Zisman A, Wieder JA, Pantuck AJ, et al. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol 2003; 169:909-916.
59. Kim HL, Zisman A, Han KR, et al. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? [see comment]. J Urol 2004; 171:588-591.
60. Libertino JA, Zinman L, Watkins E Jr. Long-term results of resection of renal cell cancer with extension into inferior vena cava. J Urol 1987; 137:21-24.
61. Montie JE, Pontes JE, Novick AC, et al. Resection of inferior vena cava tumor thrombi from renal cell carcinoma. Am Surg 1991; 57:56-61.
62. Glazer AA, Novick AC. Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol 1996; 155:448-450.
63. Ficarra V, Righetti R, D'Amico A, et al. Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology 2001; 61:10-15.
64. Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol 2004; 171:598-601.
65. Uzzo RG, Cherullo EE, Myles J, et al. Renal cell carcinoma invading the urinary collecting system: implications for staging. J Urol 2002; 167:2392-2396.
66. Palapattu GS, Pantuck AJ, Dorey F, et al. Collecting system invasion in renal cell carcinoma: impact on prognosis and nature staging strategies. J Urol 2003; 170:768-772.
67. Gelb AB. Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80:981-986.
68. Srigley JR, Hutter RV, Gelb AB, et al. Current prognostic factors-renal cell carcinoma: Workgroup No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80:994-996.
69. Bechtold RE, Zagoria RJ. Imaging approach to staging of renal cell carcinoma. Urol Clin North Am 1997; 24:507-522.
70. Choyke PL, Newhouse JH, Bluth EL, et al. Renal cell carcinoma staging. In: American College of Radiology ACR Appropriateness Criteria; 2001.
71. Pretorius ES, Wickstrom ML, Siegelman ES. MR imaging of renal neoplasms. Magn Reson Imaging Clin N Am 2000; 8:813-836.
72. Choyke PL. Detection and staging of renal cancer. Magn Reson Imaging Clin N Am 1997; 5:29-47.
73. Israel GM, Bosniak MA. Renal imaging for diagnosis and staging of renal cell carcinoma. Urol Clinics North Am 2003; 30:499-514.
74. Ergen FB, Hussain HK, Caoili EM, et al. MRI for preoperative staging of renal cell carcinoma using the 1997 TNM classification: comparison with surgical and pathologic staging. Am J Roentgenol 2004; 182:217-225.
75. Hallscheidt PJ, Bock M, Riedasch G, et al. Diagnostic accuracy of staging renal cell carcinomas using multidetector-row computed tomography and magnetic resonance imaging: a prospective study with histopathologk correlation. J Comput Assist Tomogr 2004; 28:333-339.
76. Seaman E, Goluboff ET, Ross S, et al. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology 1996; 48:692-695.
77. Shvarts O, Lam JS, Kim HL, et al. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol 2004; 172:867-870.
78. Lim DJ, Carter MF. Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. J Urol 1993; 150:1112-1114.
79. Ramdave S, Thomas GW, Berlangieri SU, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. [see comment] J Urol 2001; 166:825-830.
80. Jadvar H, Kherbache HM, Pinski JK, et al. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol 2003; 60:395-400.
81. Kang DE, White RL Jr, Zuger JH, et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004; 171:1806-1809.
82. Leung AC, Ghavamian R. Advances in the staging of renal cell carcinoma. Expert Rev Anticancer Ther 2002; 2:673-680.
83. Kamel IR, Hochman MG, Keogan MT, et al. Accuracy of breath-hold magnetic resonance imaging in preoperative staging of organ-confined renal cell carcinoma. J Comput Assist Tomogr 2004; 28:327-332.
84. Tsui KH, Shvarts O, Barbaric Z, et al. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectormes. J Urol 2000; 163:437-441.
85. Kobayashi T, Nakamura E, Yamamoto S, et al. Low incidence of ipsilateral adrenal involvement and recurrences in patients with renal cell carcinoma undergoing radical nephrectomy: a retrospective analysis of 393 patients. Urology 2003; 62:40-45.
86. Sawai Y, Kinouchi T, Mano M, et al. Ipsilateral adrenal involvement from renal cell carcinoma: retrospective study of the predictive value of computed tomography. Urology 2002; 59:28-31.
87. Studer UE, Scherz S, Scheidegger J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 1990; 144:243-245.
88. Zisman A, Pantuck AJ, Figlin RA, et al. Validation of the ucla integrated staging system for patients with renal cell carcinoma. J Clin Oncol 2001; 19:3792-3793.
89. Kattan MW, Reuter V, Motzer RJ, et al. A postopetative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166:63-67.
90. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168:2395-2400.
91. Patard JJ, Leray E, Cindolo L, et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol 2004; 172:858-862.
92. Lane BR, Kattan MW. Predicting outcomes in renal cell carcinoma. Curr Opin Urol 2005; 15:289-297.
93. Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004; 171:2461-2466.
94. Lam JS, Shvarts O, Leppert JT, et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005; 174:466-472.